Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left … (NCT06279351) | Clinical Trial Compass
RecruitingPhase 2
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
China96 participantsStarted 2024-08-11
Plain-language summary
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application.
2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing;
✓. Physical state is good: PS 0-2;
✓. Expected survival of more than 3 months;
✓. Aged 18-75 years old;
✓. Have not received systematic chemotherapy before;
✓. Did not receive cetuximab treatment;
✓. Liver, kidney and bone marrow functions are basically normal;
✓. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;
Exclusion criteria
✕. Patients with severe dysfunction of vital organs (heart, liver, kidney);